Kongenitaler Hyperinsulinismus

ZUSAMMENFASSUNG

Bereits in den 1950er-Jahren wurde eine Familie mit leuzinsensitiver Hypoglykämie beschrieben, die erstmals eine genetische Ursache der „idiopathischen Hypoglykämie des Säuglings McQuarry“ vermuten ließ. Jedoch erst in den 1990er-Jahren konnten genetische Ursachen des damals unspezifisch als Nesidioblastose bezeichneten kongenitalen Hyperinsulinismus nachgewiesen werden. Diese Erkenntnisse zur Pathogenese führten bereits wenige Jahre später zur lebenslangen Heilung für etwa ein Drittel der zuvor intensivmedizinisch betreuten Säuglinge. Bei dieser Teilgruppe liegt ein umschriebener hochaktiver Fokus im Pankreas vor, der häufig laparoskopisch entfernt werden kann. Auch für die medikamentöse Therapie gibt es den Ausblick auf eine Präzisionstherapie mit löslichem Glukagon, spezifischem Insulinrezeptorantikörper und einem spezifischen GLP-1-Antagonisten.

ABSTRACT

As early as the 1950 s, a family with leucine-sensitive hypoglycaemia was described, which for the first time suggested a genetic cause of “idiopathic hypoglycaemia of the infant McQuarry”. However, it was not until the 1990 s that genetic causes of congenital hyperinsulinism, then unspecifically referred to as nesidioblastosis, were identified. Just a few years later, these findings on the pathogenesis led to a lifelong cure for around a third of the infants previously receiving intensive medical care. In this subgroup, there is a circumscribed highly active focus in the pancreas, which can often be removed laparoscopically. There is also the prospect of precision drug therapy with soluble glucagon, specific insulin receptor antibodies and a specific GLP-1 antagonist.

Schlüsselwörter

Kongenitaler Hyperinsulinismus - neonatale Hypoglykämie - fokaler KATP Hyperinsulinismus - 18F-DOPA-PET-Scan - Diazoxid - lösliches Glukagon

Keywords

Congenital hyperinsulinism - neonatal hypoglycemia - focal form of KATP HI - 18F-DOPA-PET-scan - diazoxide - soluble glucagon

Publikationsverlauf

Artikel online veröffentlicht:
02. Dezember 2024

• Literatur

• 1 Cochrane WA, Payne WW, Simpkiss MJ. et al Familial hypoglycemia precipitated by amino acids. J Clin Invest 1956; 35: 411-422
• 2 McQuarrie I. Idiopathic spontaneously occurring hypoglycemia in infants; clinical significance of problem and treatment. AMA Am J Dis Child 1954; 87: 399-428
• 3 Thomas PM, Cote GJ, Wohllk N. et al Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995; 268: 426-429
• 4 Barthlen W, Varol E, Empting S. et al Surgery in Focal Congenital Hyperinsulinism (CHI) – The “Hyperinsulinism Germany International” Experience in 30 Children. Pediatr Endocrinol Rev 2016; 14: 129-137
• 5 Thornton PS, De Leon DD, Empting S. et al Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children. J Clin Endocrinol Metab 2024; 109: 1071-1079
• 6 Danowitz M, De Leon DD. The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Front Endocrinol (Lausanne) 2022; 13: 863184
• 7 De Leon DD, Arnoux JB, Banerjee I. et al International Guidelines for the Diagnosis and Management of Hyperinsulinism Horm Res Paediatr 2023. 10.1159/000531766. doi:10.1159/000531766.
• 8 Stanley CA, Rozance PJ, Thornton PS. et al Re-evaluating “transitional neonatal hypoglycemia”: mechanism and implications for management. J Pediatr 2015; 166: 1520-1525 e1521
• 9 Larsen AR, Brusgaard K, Christesen HT. et al Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia Histol Histopathol. 2024 doi. 10.14670/HH-18–709: 18709. doi: 10.14670/HH-18–709.
• 10 Ferrara C, Patel P, Becker S. et al Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children. J Pediatr 2016; 168: 212-219
• 11 Sakakibara A, Hashimoto Y, Kawakita R. et al Diagnosis of congenital hyperinsulinism: Biochemical profiles during hypoglycemia. Pediatr Diabetes 2018; 19: 259-264
• 12 Gray KD, Dudash K, Escobar C. et al Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018; 38: 1496-1502
• 13 Bailey MJ, Rout A, Harding JE. et al Prolonged transitional neonatal hypoglycaemia: characterisation of a clinical syndrome. J Perinatol 2021; 41: 1149-1157
• 14 Yang J, Hammoud B, Li C. et al Decreased KATP Channel Activity Contributes to the Low Glucose Threshold for Insulin Secretion of Rat Neonatal Islets. Endocrinology 2021; 162
• 15 Hoe FM, Thornton PS, Wanner LA. et al Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. J Pediatr 2006; 148: 207-212
• 16 Yamada Y, Kitayama K, Oyachi M. et al Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017–2018): Congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome (Hirata’s disease). J Diabetes Investig 2020; 11: 554-563
• 17 Lapidus D, De Leon DD, Thornton PS. et al The Birth Prevalence of Congenital Hyperinsulinism: A Narrative Review of the Epidemiology of a Rare Disease Horm Res Paediatr 2024. 10.1159/000539464: 1–8.
• 18 Zenker M, Mohnike K, Palm K. Syndromic forms of congenital hyperinsulinism. Front Endocrinol (Lausanne) 2023; 14: 1013874
• 19 Banerjee I, Senniappan S, Laver TW. et al Refinement of the critical genomic region for congenital hyperinsulinism in the Chromosome 9p deletion syndrome. Wellcome Open Res 2019; 4: 149
• 20 Snider KE, Becker S, Boyajian L. et al Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab 2013; 98: E355-363
• 21 Weinzimer SA, Stanley CA, Berry GT. et al A syndrome of congenital hyperinsulinism and hyperammonemia. J Pediatr 1997; 130: 661-664
• 22 Molven A, Matre GE, Duran M. et al Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. Diabetes 2004; 53: 221-227
• 23 Hsu BY, Kelly A, Thornton PS. et al Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome. J Pediatr 2001; 138: 383-389
• 24 Kapoor RR, James C, Flanagan SE. et al 3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity. J Clin Endocrinol Metab 2009; 94: 2221-2225
• 25 Zhang X, Jiang S, Zhang R. et al Review of published 467 achondroplasia patients: clinical and mutational spectrum. Orphanet J Rare Dis 2024; 19: 29
• 26 Otonkoski T, Jiao H, Kaminen-Ahola N. et al Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. Am J Hum Genet 2007; 81: 467-474
• 27 Sayed S, Langdon DR, Odili S. et al Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes 2009; 58: 1419-1427
• 28 Padidela R, Fiest M, Arya V. et al Insulinoma in childhood: clinical, radiological, molecular and histological aspects of nine patients. Eur J Endocrinol 2014; 170: 741-747
• 29 Boodhansingh KE, Yang Z, Li C. et al Localized islet nuclear enlargement hyperinsulinism (LINE-HI) due to ABCC8 and GCK mosaic mutations. Eur J Endocrinol 2022; 187: 301-313
• 30 Sempoux C, Capito C, Bellanne-Chantelot C. et al Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. J Clin Endocrinol Metab 2011; 96: 3785-3793
• 31 Vossschulte H, Mohnike K, Mohnike K. et al Correlation of PET-MRI, Pathology, LOH, and Surgical Success in a Case of CHI With Atypical Large Pancreatic Focus. J Endocr Soc 2022; 6: bvac056
• 32 Wieland I, Schanze I, Felgendreher IM. et al Integration of genomic analysis and transcript expression of ABCC8 and KCNJ11 in focal form of congenital hyperinsulinism. Front Endocrinol (Lausanne) 2022; 13: 1015244
• 33 Mohnike K, Wieland I, Barthlen W. et al Clinical and genetic evaluation of patients with KATP channel mutations from the German registry for congenital hyperinsulinism. Horm Res Paediatr 2014; 81: 156-168
• 34 States LJ. Saade-Lemus S, De Leon DD. 18-F-L 3,4-Dihydroxyphenylalanine PET/Computed Tomography in the Management of Congenital Hyperinsulinism. PET Clin 2020; 15: 349-359
• 35 Garg PK, Putegnat B, Truong L. et al Visual interpretation, not SUV ratios, is the ideal method to interpret 18F-DOPA PET scans to aid in the cure of patients with focal congenital hyperinsulinism. PLoS One 2020; 15: e0241243
• 36 Mohnike K, Blankenstein O, Christesen HT. et al Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 2006; 66: 40-42
• 37 Boss M, Rottenburger C, Brenner W. et al (68)Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism J Nucl Med. 2021 doi: 10.2967/jnumed.121.262327. doi: 10.2967/jnumed.121.262327.
• 38 Banerjee I, Sajjan R, Estebanez MS. et al (68)Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication. J Nucl Med 2022; 63: 493
• 39 von Rohden L, Mohnike K, Mau H. et al Intraoperative sonography: a technique for localizing focal forms of congenital hyperinsulinism in the pancreas. Ultraschall Med 2011; 32: 74-80
• 40 Narvey MR, Marks SD. The screening and management of newborns at risk for low blood glucose. Paediatr Child Health 2019; 24: 536-554
• 41 Thornton PS, Stanley CA, De Leon DD. et al Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr 2015; 167: 238-245
• 42 Wackernagel D, Gustafsson A, Edstedt Bonamy AK. et al Swedish national guideline for prevention and treatment of neonatal hypoglycaemia in newborn infants with gestational age > / = 35 weeks Acta Paediatr 2019. doi: 10.1111/apa.14955. doi:10.1111/apa.14955.
• 43 Muller TD, Finan B, Clemmensen C. et al The New Biology and Pharmacology of Glucagon. Physiol Rev 2017; 97: 721-766
• 44 Salomon-Estebanez M, Yau D, Dunne MJ. et al Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series. Front Endocrinol (Lausanne) 2020; 11: 441
• 45 Hawkes CP, Lado JJ, Givler S. et al The Effect of Continuous Intravenous Glucagon on Glucose Requirements in Infants with Congenital Hyperinsulinism. JIMD Rep 2019; 45: 45-50
• 46 Coughlin CC, Roy SM, Arkin LM. et al Iatrogenic Necrolytic Migratory Erythema in an Infant with Congenital Hyperinsulinism. Pediatr Dermatol 2016; 33: e43-47
• 47 Wald M, Lawrenz K, Luckner D. et al Glucagon therapy as a possible cause of erythema necrolyticum migrans in two neonates with persistent hyperinsulinaemic hypoglycaemia. Eur J Pediatr 2002; 161: 600-603
• 48 Drash A, Wolff F. Drug Therapy in Leucine-Sensitive Hypoglycemia. Metabolism 1964; 13: 487-492
• 49 Herrera A, Vajravelu ME, Givler S. et al Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. J Clin Endocrinol Metab 2018; 103: 4365-4372
• 50 Thornton P, Truong L, Reynolds C. et al Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism. Horm Res Paediatr 2019; 91: 25-32
• 51 Pasquini TLS, Mesfin M, Schmitt J. et al Global Registries in Congenital Hyperinsulinism. Front Endocrinol 2022; 13: 876903
• 52 Timlin MR, Black AB, Delaney HM. et al Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review. Pediatr Cardiol 2017; 38: 1247-1250
• 53 Brar PC, Heksch R, Cossen K. et al Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism J Clin Endocrinol Metab. 2020; 105. Doi: 10.1210/clinem/dgaa543.
• 54 Vajravelu ME, Congdon M, Mitteer L. et al Continuous Intragastric Dextrose: A Therapeutic Option for Refractory Hypoglycemia in Congenital Hyperinsulinism. Horm Res Paediatr 2019; 91: 62-68
• 55 Adzick NS, De Leon DD, States LJ. et al Surgical treatment of congenital hyperinsulinism: Results from 500 pancreatectomies in neonates and children. J Pediatr Surg 2019; 54: 27-32
• 56 Suchi M, Thornton PS, Adzick NS. et al Congenital hyperinsulinism: intraoperative biopsy interpretation can direct the extent of pancreatectomy. Am J Surg Pathol 2004; 28: 1326-1335
• 57 Barthlen W, Mohnike W, Mohnike K. Techniques in pediatric surgery: congenital hyperinsulinism. Horm Res Paediatr 2011; 75: 304-310
• 58 Henquin JC, Sempoux C, Marchandise J. et al Congenital hyperinsulinism caused by hexokinase I expression or glucokinase-activating mutation in a subset of beta-cells. Diabetes 2013; 62: 1689-1696
• 59 Glaser B, Landau H, Smilovici A. et al Persistent hyperinsulinaemic hypoglycaemia of infancy: long-term treatment with the somatostatin analogue Sandostatin. Clin Endocrinol (Oxf) 1989; 31: 71-80
• 60 Thornton PS, Alter CA, Katz LE. et al Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993; 123: 637-643
• 61 Mooij CF, Tacke CE, van Albada ME. et al Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation. Ann Pediatr Endocrinol Metab 2021; 26: 278-283
• 62 Le Quan Sang KH, Arnoux JB, Mamoune A. et al Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012; 166: 333-339
• 63 van der Steen I, van Albada ME, Mohnike K. et al A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism. Horm Res Paediatr 2018; 89: 82-89
• 64 Modan-Moses D, Koren I, Mazor-Aronovitch K. et al Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011; 96: 2312-2317
• 65 Laje P, Halaby L, Adzick NS. et al Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010; 11: 142-147
• 66 McMahon AW, Wharton GT, Thornton P. et al Octreotide use and safety in infants with hyperinsulinism. Pharmacoepidemiol Drug Saf 2017; 26: 26-31
• 67 Avatapalle B, Padidela R, Randell T. et al Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism. BMJ Case Rep 2012; 2012
• 68 Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia Ther Adv Endocrinol Metab. 2020; 11 2042018820965068 doi:10.1177/2042018820965068.
• 69 Flanagan SE, Vairo F, Johnson MB. et al A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia. Pediatr Diabetes 2017; 18: 320-323
• 70 Senniappan S, Alexandrescu S, Tatevian N. et al Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med 2014; 370: 1131-1137
• 71 Banerjee I, De Leon D, Dunne MJ. Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient. Orphanet J Rare Dis 2017; 12: 70
• 72 Haliloglu B, Tuzun H, Flanagan SE. et al Sirolimus-Induced Hepatitis in Two Patients with Hyperinsulinemic Hypoglycemia. J Clin Res Pediatr Endocrinol 2018; 10: 279-283
• 73 Mohnike K, Blankenstein O, Pfuetzner A. et al Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 2008; 70: 59-64
• 74 Laje P, Stanley CA, Palladino AA. et al Pancreatic head resection and Roux-en-Y pancreaticojejunostomy for the treatment of the focal form of congenital hyperinsulinism. J Pediatr Surg 2012; 47: 130-135
• 75 Yorifuji T, Horikawa R, Hasegawa T. et al Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol 2017; 26: 127-152
• 76 Beltrand J, Caquard M, Arnoux JB. et al Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012; 35: 198-203
• 77 Arya VB, Senniappan S, Demirbilek H. et al Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS One 2014; 9: e98054
• 78 Salomon-Estebanez M, Flanagan SE, Ellard S. et al Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time. Orphanet J Rare Dis 2016; 11: 163
• 79 Kumaran A, Kar S, Kapoor RR. et al The clinical problem of hyperinsulinemic hypoglycemia and resultant infantile spasms. Pediatrics 2010; 126: e1231-1236
• 80 Ludwig A, Enke S, Heindorf J. et al Formal Neurocognitive Testing in 60 Patients with Congenital Hyperinsulinism. Horm Res Paediatr 2018; 89: 1-6
• 81 Meissner T, Wendel U, Burgard P. et al Long-term follow-up of 114 patients with congenital hyperinsulinism. European Journal of Endocrinology 2003; 149: 43-51
• 82 Menni F, de Lonlay P, Sevin C. et al Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 2001; 107: 476-479
• 83 Avatapalle HB, Banerjee I, Shah S. et al Abnormal Neurodevelopmental Outcomes are Common in Children with Transient Congenital Hyperinsulinism. Front Endocrinol (Lausanne) 2013; 4: 60
• 84 Muukkonen L, Mannisto J, Jaaskelainen J. et al The effect of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism. Dev Med Child Neurol 2019; 61: 451-457
• 85 Palladino AA, Stanley CA. The hyperinsulinism/hyperammonemia syndrome. Rev Endocr Metab Disord 2010; 11: 171-178
• 86 Banerjee I, Forsythe L, Skae M. et al Feeding Problems Are Persistent in Children with Severe Congenital Hyperinsulinism Front Endocrinol (Lausanne) 2016; 7: 8
• 87 Welters A, Meissner T, Grulich-Henn J. et al Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism. Orphanet J Rare Dis 2018; 13: 230
• 88 Makov M, Chodick G, Mohnike K. et al Congenital hyperinsulinism, neonatal diabetes and the risk of malignancies: an international collaborative study. Preliminary communication. Diabet Med 2015; 32: 701-703